<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435825</url>
  </required_header>
  <id_info>
    <org_study_id>WV19432</org_study_id>
    <nct_id>NCT00435825</nct_id>
  </id_info>
  <brief_title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).</brief_title>
  <official_title>A Randomized, Double-blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 4 arm study will compare the efficacy and safety of PEGASYS given for 24 or 48 weeks,
      and at doses of 90 or 180 micrograms weekly, in the treatment of HBeAg positive patients with
      chronic hepatitis B. Patients will be randomized to one of 4 treatment groups: a)PEGASYS 90
      micrograms subcutaneous (sc) weekly for 24 weeks, b)PEGASYS 180 micrograms sc weekly for 24
      weeks, c)PEGASYS 90 micrograms sc weekly for 48 weeks or d)PEGASYS 180 micrograms sc weekly
      for 48 weeks. Following treatment there will be a 24 week period of treatment-free follow-up
      in all treatment groups for the primary endpoint. The anticipated time on study treatment is
      3-12 months, and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected for HBeAg. HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe) determined at 24 weeks after the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Blood was collected for HBeAg. HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBs) determined at Week 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Loss of Hepatitis Be Antigen (HBeAg) 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected HBeAg 24 Weeks following the end of treatment. Loss of HBeAg is defined as the absence of HBeAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion 24 Weeks Following the End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs) determined at 24 weeks after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected for HBsAg 24 weeks following the end of treatment. Loss of HBsAg is defined as the absence of HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Alanine Aminotransferase (ALT)</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected 24 weeks following the end of treatment for ALT and was analyzed at a local laboratory. A normal ALT is a value within the normal range of the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 20,000 IU/mL 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected for HBV-DNA 24 weeks following the end of treatment and was analyzed at the central laboratory using the Roche approved polymerase chain reaction (PCR) methodology. Percentage of participants with a HBV-DNA suppression of &lt; 20,000 IU/mL (Less than 100,000 copies/mL) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hepatitis Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 2,000 IU/mL 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment of Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected for HBV-DNA and was analyzed at the central laboratories using the Roche approved PCR methodology 24 weeks following the end of treatment. Percentage of participants with A HBV-DNA Suppression of &lt; 2,000 IU/mL (Less than 10,000 copies/mL) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Combined Endpoint Response 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Combined endpoint was defined as HBeAg seroconversion, a normal serum ALT and HBV-DNA suppression below 20,000 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Dual Endpoint Response 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Dual endpoint was defined as the achievement of both HBeAg seroconversion and a HBV-DNA &lt;2,000 IU/ml (Less than 10,000 copies/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Serum Alanine Aminotransferase (ALT) 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected 24 weeks following the end of treatment for ALT and was analyzed at a local laboratory. A normal ALT is a value within the normal range of the assay: 0- 55 units/liter (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative HBV-DNA 24 Weeks Following End of Treatment</measure>
    <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
    <description>Blood was collected for HBV-DNA and was analyzed at the central laboratories using the Roche approved PCR methodology 24 weeks following the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">551</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>peginterferon alfa-2a 90 μg_24 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peginterferon alfa-2a 180 μg_24 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peginterferon alfa-2a 90 μg_48 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peginterferon alfa-2a 180 μg_48 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.</description>
    <arm_group_label>peginterferon alfa-2a 90 μg_24 Weeks</arm_group_label>
    <arm_group_label>peginterferon alfa-2a 180 μg_24 Weeks</arm_group_label>
    <arm_group_label>peginterferon alfa-2a 90 μg_48 Weeks</arm_group_label>
    <arm_group_label>peginterferon alfa-2a 180 μg_48 Weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;

          -  positive Hepatitis B surface antigen (HBsAg) for &gt;6 months, positive HBeAg, HBV DNA
             &gt;500,000 copies/mL, and anti-HBs negative;

          -  liver disease consistent with Chronic Hepatitis B.

        Exclusion Criteria:

          -  antiviral therapy for CHB within previous 6 months;

          -  co-infection with Hepatitis A virus (HAV), Hepatitis C virus (HCV), Hepatitis D virus
             (HDV) or Human immuno deficiency virus (HIV);

          -  evidence of decompensated liver disease;

          -  medical condition associated with chronic liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenslopes</city>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <zip>13081-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <zip>40150-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hunan</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>100</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <zip>443021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50202</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Songkhla</city>
        <zip>90112</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2007</study_first_posted>
  <results_first_submitted>March 20, 2013</results_first_submitted>
  <results_first_submitted_qc>June 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2013</results_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
          <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
          <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
          <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
          <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="136"/>
                <participants group_id="P4" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 24 Weeks Treatment</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 48 Weeks Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123">Completed is the number of participants who received study treatment and completed follow-up.</participants>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormality of Laboratory Test</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not enter follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete full follow-up period</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Measures are based on participants from the Intent-to-treat population who received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
          <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
          <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
          <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
          <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="136"/>
            <count group_id="B4" value="136"/>
            <count group_id="B5" value="548"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="9.77" lower_limit="18" upper_limit="56"/>
                    <measurement group_id="B2" value="33.0" spread="10.52" lower_limit="18" upper_limit="66"/>
                    <measurement group_id="B3" value="33.8" spread="10.48" lower_limit="16" upper_limit="62"/>
                    <measurement group_id="B4" value="33.3" spread="10.89" lower_limit="18" upper_limit="69"/>
                    <measurement group_id="B5" value="32.98" lower_limit="16" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion 24 Weeks Following End of Treatment</title>
        <description>Blood was collected for HBeAg. HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe) determined at 24 weeks after the end of treatment.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion 24 Weeks Following End of Treatment</title>
          <description>Blood was collected for HBeAg. HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe) determined at 24 weeks after the end of treatment.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.08" lower_limit="8.82" upper_limit="20.91"/>
                    <measurement group_id="O2" value="22.86" lower_limit="16.19" upper_limit="30.71"/>
                    <measurement group_id="O3" value="25.76" lower_limit="18.54" upper_limit="34.09"/>
                    <measurement group_id="O4" value="36.15" lower_limit="27.91" upper_limit="45.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion at Week 72</title>
        <description>Blood was collected for HBeAg. HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBs) determined at Week 72.</description>
        <time_frame>Week 72</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion at Week 72</title>
          <description>Blood was collected for HBeAg. HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBs) determined at Week 72.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.31" lower_limit="12.32" upper_limit="25.67"/>
                    <measurement group_id="O2" value="27.14" lower_limit="19.98" upper_limit="35.30"/>
                    <measurement group_id="O3" value="25.76" lower_limit="18.54" upper_limit="34.09"/>
                    <measurement group_id="O4" value="36.15" lower_limit="27.91" upper_limit="45.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Loss of Hepatitis Be Antigen (HBeAg) 24 Weeks Following End of Treatment</title>
        <description>Blood was collected HBeAg 24 Weeks following the end of treatment. Loss of HBeAg is defined as the absence of HBeAg.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the Per protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Loss of Hepatitis Be Antigen (HBeAg) 24 Weeks Following End of Treatment</title>
          <description>Blood was collected HBeAg 24 Weeks following the end of treatment. Loss of HBeAg is defined as the absence of HBeAg.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the Per protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.79" lower_limit="9.39" upper_limit="21.71"/>
                    <measurement group_id="O2" value="22.86" lower_limit="16.19" upper_limit="30.71"/>
                    <measurement group_id="O3" value="26.52" lower_limit="19.21" upper_limit="34.90"/>
                    <measurement group_id="O4" value="36.15" lower_limit="27.91" upper_limit="45.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion 24 Weeks Following the End of Treatment</title>
        <description>HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs) determined at 24 weeks after the end of treatment.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion 24 Weeks Following the End of Treatment</title>
          <description>HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs) determined at 24 weeks after the end of treatment.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.56"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.60"/>
                    <measurement group_id="O3" value="1.52" lower_limit="0.18" upper_limit="5.37"/>
                    <measurement group_id="O4" value="2.31" lower_limit="0.48" upper_limit="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) 24 Weeks Following End of Treatment</title>
        <description>Blood was collected for HBsAg 24 weeks following the end of treatment. Loss of HBsAg is defined as the absence of HBsAg.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) 24 Weeks Following End of Treatment</title>
          <description>Blood was collected for HBsAg 24 weeks following the end of treatment. Loss of HBsAg is defined as the absence of HBsAg.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.02" upper_limit="3.86"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="2.60"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.47" upper_limit="6.50"/>
                    <measurement group_id="O4" value="2.31" lower_limit="0.48" upper_limit="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Alanine Aminotransferase (ALT)</title>
        <description>Blood was collected 24 weeks following the end of treatment for ALT and was analyzed at a local laboratory. A normal ALT is a value within the normal range of the assay.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Alanine Aminotransferase (ALT)</title>
          <description>Blood was collected 24 weeks following the end of treatment for ALT and was analyzed at a local laboratory. A normal ALT is a value within the normal range of the assay.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.28" lower_limit="22.86" upper_limit="38.55"/>
                    <measurement group_id="O2" value="30.71" lower_limit="23.20" upper_limit="39.06"/>
                    <measurement group_id="O3" value="43.18" lower_limit="34.59" upper_limit="52.08"/>
                    <measurement group_id="O4" value="52.31" lower_limit="43.37" upper_limit="61.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 20,000 IU/mL 24 Weeks Following End of Treatment</title>
        <description>Blood was collected for HBV-DNA 24 weeks following the end of treatment and was analyzed at the central laboratory using the Roche approved polymerase chain reaction (PCR) methodology. Percentage of participants with a HBV-DNA suppression of &lt; 20,000 IU/mL (Less than 100,000 copies/mL) is reported.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 20,000 IU/mL 24 Weeks Following End of Treatment</title>
          <description>Blood was collected for HBV-DNA 24 weeks following the end of treatment and was analyzed at the central laboratory using the Roche approved polymerase chain reaction (PCR) methodology. Percentage of participants with a HBV-DNA suppression of &lt; 20,000 IU/mL (Less than 100,000 copies/mL) is reported.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.83" lower_limit="15.34" upper_limit="29.53"/>
                    <measurement group_id="O2" value="21.43" lower_limit="14.95" upper_limit="29.16"/>
                    <measurement group_id="O3" value="32.58" lower_limit="24.68" upper_limit="41.27"/>
                    <measurement group_id="O4" value="42.31" lower_limit="33.70" upper_limit="51.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hepatitis Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 2,000 IU/mL 24 Weeks Following End of Treatment</title>
        <description>Blood was collected for HBV-DNA and was analyzed at the central laboratories using the Roche approved PCR methodology 24 weeks following the end of treatment. Percentage of participants with A HBV-DNA Suppression of &lt; 2,000 IU/mL (Less than 10,000 copies/mL) is reported.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment of Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 2,000 IU/mL 24 Weeks Following End of Treatment</title>
          <description>Blood was collected for HBV-DNA and was analyzed at the central laboratories using the Roche approved PCR methodology 24 weeks following the end of treatment. Percentage of participants with A HBV-DNA Suppression of &lt; 2,000 IU/mL (Less than 10,000 copies/mL) is reported.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" lower_limit="6.58" upper_limit="17.65"/>
                    <measurement group_id="O2" value="11.43" lower_limit="6.68" upper_limit="17.90"/>
                    <measurement group_id="O3" value="22.73" lower_limit="15.89" upper_limit="30.83"/>
                    <measurement group_id="O4" value="30.0" lower_limit="22.28" upper_limit="38.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Combined Endpoint Response 24 Weeks Following End of Treatment</title>
        <description>Combined endpoint was defined as HBeAg seroconversion, a normal serum ALT and HBV-DNA suppression below 20,000 IU/mL.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Combined Endpoint Response 24 Weeks Following End of Treatment</title>
          <description>Combined endpoint was defined as HBeAg seroconversion, a normal serum ALT and HBV-DNA suppression below 20,000 IU/mL.</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" lower_limit="3.93" upper_limit="13.44"/>
                    <measurement group_id="O2" value="15.0" lower_limit="9.53" upper_limit="22.01"/>
                    <measurement group_id="O3" value="17.42" lower_limit="11.38" upper_limit="24.99"/>
                    <measurement group_id="O4" value="31.54" lower_limit="23.67" upper_limit="40.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Dual Endpoint Response 24 Weeks Following End of Treatment</title>
        <description>Dual endpoint was defined as the achievement of both HBeAg seroconversion and a HBV-DNA &lt;2,000 IU/ml (Less than 10,000 copies/mL).</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Dual Endpoint Response 24 Weeks Following End of Treatment</title>
          <description>Dual endpoint was defined as the achievement of both HBeAg seroconversion and a HBV-DNA &lt;2,000 IU/ml (Less than 10,000 copies/mL).</description>
          <population>Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation. Patients were analyzed according to the treatment received, rather than the randomized treatment. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" lower_limit="3.93" upper_limit="13.44"/>
                    <measurement group_id="O2" value="9.29" lower_limit="5.04" upper_limit="15.36"/>
                    <measurement group_id="O3" value="13.64" lower_limit="8.29" upper_limit="20.69"/>
                    <measurement group_id="O4" value="24.62" lower_limit="17.49" upper_limit="32.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Serum Alanine Aminotransferase (ALT) 24 Weeks Following End of Treatment</title>
        <description>Blood was collected 24 weeks following the end of treatment for ALT and was analyzed at a local laboratory. A normal ALT is a value within the normal range of the assay: 0- 55 units/liter (U/L).</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Participants from the Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation who had data available for analysis. Patients were analyzed according to the treatment received. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Serum Alanine Aminotransferase (ALT) 24 Weeks Following End of Treatment</title>
          <description>Blood was collected 24 weeks following the end of treatment for ALT and was analyzed at a local laboratory. A normal ALT is a value within the normal range of the assay: 0- 55 units/liter (U/L).</description>
          <population>Participants from the Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation who had data available for analysis. Patients were analyzed according to the treatment received. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.84" upper_limit="1.96"/>
                    <measurement group_id="O2" value="1.97" lower_limit="1.90" upper_limit="2.05"/>
                    <measurement group_id="O3" value="1.90" lower_limit="1.82" upper_limit="1.98"/>
                    <measurement group_id="O4" value="1.73" lower_limit="1.67" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative HBV-DNA 24 Weeks Following End of Treatment</title>
        <description>Blood was collected for HBV-DNA and was analyzed at the central laboratories using the Roche approved PCR methodology 24 weeks following the end of treatment.</description>
        <time_frame>24 Weeks following end of treatment (Week 48 for 24 Week Treatment or Week 72 for 48 Week Treatment)</time_frame>
        <population>Participants from the Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation who had data available for analysis. Patients were analyzed according to the treatment received. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
            <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
            <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
            <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative HBV-DNA 24 Weeks Following End of Treatment</title>
          <description>Blood was collected for HBV-DNA and was analyzed at the central laboratories using the Roche approved PCR methodology 24 weeks following the end of treatment.</description>
          <population>Participants from the Per-protocol population defined as all participants who received study drug and who did not have any major protocol deviation who had data available for analysis. Patients were analyzed according to the treatment received. 10 patients in the per-protocol population switched treatment groups for the analysis.</population>
          <units>IU/mL Log10</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" lower_limit="5.93" upper_limit="6.72"/>
                    <measurement group_id="O2" value="6.38" lower_limit="5.99" upper_limit="6.76"/>
                    <measurement group_id="O3" value="5.98" lower_limit="5.51" upper_limit="6.45"/>
                    <measurement group_id="O4" value="5.29" lower_limit="4.81" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety set included randomized patients who received study drug and had at least 1 post-baseline assessment. 1 patient in the PEG-IFN 180 μg 24 week arm had no post-baseline assessments. 10 patients actually received drug for less time and switched arms for analysis (4 PEG-IFN 90 μg 48 weeks to 24 weeks and 6 PEG-IFN 180 μg 48 weeks to 24 weeks.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon Alfa-2a 90 μg_24 Weeks</title>
          <description>Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Peginterferon Alfa-2a 180 μg_24 Weeks</title>
          <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Peginterferon Alfa-2a 90 μg_48 Weeks</title>
          <description>Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Peginterferon Alfa-2a 180 μg_48 Weeks</title>
          <description>Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

